Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
other information
Study period:
September to October 1996
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: guideline study with restriction (actual ingested doses differ from intended dose levels)

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1997
Report date:
1997

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
Deviations:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
17-hydroxy-6-methylenepregn-4-ene-3,20-dione 17-acetate
EC Number:
251-133-8
EC Name:
17-hydroxy-6-methylenepregn-4-ene-3,20-dione 17-acetate
Cas Number:
32634-95-0
Molecular formula:
C24H32O4
IUPAC Name:
17-Acetoxy-6-methylene-4-pregnene-3,20-dione

Test animals

Species:
rat
Strain:
other: Han: WIST (SPF)
Sex:
male/female

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
other: 1 % Klucel LF, 0.9 % NaCl solution, 0.085 % Myrj 53 per 100 ml bidest. water
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Analysis of content was performed in one sam pie of each concentration once at the beginning and at the end of the treatment period. The results showed that the actual concentrations of the first preparation were within the acceptable range of 91 to 94% of the nominal concentrations. However, the content of the last preparation revealed only an actual content of 66% of nominal concentration for the low and mid concentration and a conte nt of 84% at the high concentration level. These results indicate that the animals might have received doses over the treatment period which were about 35% below the intended dose levels, assuming that the results of the last preparation represent the greatest deviation from the intended content.
Duration of treatment / exposure:
ca. 4 weeks (29 applications)
Frequency of treatment:
once daily
Doses / concentrationsopen allclose all
Remarks:
Doses / Concentrations:
ca. 25, 130, 650 mg/kg bw
Basis:
other: actual ingested on the basis of the results of content analysis
Remarks:
Doses / Concentrations:
40, 200, 1000 mg kg bw
Basis:
other: nominal values
No. of animals per sex per dose:
6
Control animals:
yes, concurrent vehicle

Examinations

Statistics:
For statistical evaluation the Dunnett-test was used.

Results and discussion

Results of examinations

Clinical signs:
no effects observed
Mortality:
no mortality observed
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
no effects observed
Water consumption and compound intake (if drinking water study):
no effects observed
Ophthalmological findings:
no effects observed
Haematological findings:
no effects observed
Clinical biochemistry findings:
effects observed, treatment-related
Urinalysis findings:
no effects observed
Behaviour (functional findings):
no effects observed
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
no effects observed
Histopathological findings: non-neoplastic:
no effects observed
Histopathological findings: neoplastic:
no effects observed

Effect levels

open allclose all
Dose descriptor:
NOAEL
Effect level:
650 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male/female
Dose descriptor:
NOEL
Effect level:
130 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
female
Basis for effect level:
other: increase in serum glucose levels
Dose descriptor:
NOEL
Effect level:
25 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: decrease in body weight gain; increase in serum glucose level

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

The only compound-related effects which were observed during this study were an increase in serum glucose levels in male animals from the mid-dose level onwards and in female animals at the high-dose level as weil as a slight decrease in body weight gain in males from the middose level onwards. The difference in mean body weights of male animals from the high-dose group in comparison to the controls was less than 7% on the last day of weighing (day 27). Furthermore, the reduced body weight gain was not associated with a reduced food-intake. Neither the effect on glucose levels nor the slight decrease in body weight development have to be judged as an overt sign of toxicity of the test compound, due to their slight extent and the absence of any other compound-related pathological condition. In conclusion, the low dose of ca. 25 mg /kg/day was identified as no-effect-dose in male rats and 130 mg/kg/day as no-effect-dose in female rats in the present study. The highdose level of 650 mg/kg/day was characterized as no-observable-adverse-effect dose in male and female rats.

Applicant's summary and conclusion

Executive summary:

Three groups of 6 male and 6 female rats each received daily intragastric administrations of nominal doses of 40, 200 and 1000 mg /kg, respectively, as microcrystalline suspensions at an application volume of 10 ml/kg over aperiod of ca. 4 weeks (29 applications). A control group of 6 male and 6 female rats were treated with the vehicle under the same conditions. The formulations were prepared freshly on each day of the study. The results of the formulation analyses which were performed with the first and last preparation indicated, however, that only the first formulation was prepared adequately with a conte nt of ~ 91 % of nominal concentration while the content of the last preparation lay about 35% below the intended concentration. Therefore, only approximate dose ranges can be stated for the three compound-treated animal groups. The lower limits of the actual dose ranges per group were based here on the assumption that the analysis results of the last preparation indicate the"worst case" of underdosing wh ich might have occurred throughout the study.

The effects of the test substance were evaluated using clinical, biochemical and hematological parameters as weil as bone marrow examination, urinalysis, coagulation studies, necropsy findings, organ weight analysis and microscopic examinations.

The intragastric treatment of rats with the test substance over ca. 4 weeks up to a dose of ca. 650 mg/kg/day produced a slight reduction of body weight gain and an increase in serum glucose levels, but did not lead to overt signs of toxicity. Furthermore, the low dose level of ca. 25 mg kg/day was identified as no-observableeffect-dose in male rats and 130 mg/kg/day as no-observable-effect-dose in female rats in the present study.